Extended Data Fig. 3: ctDNA-based MRD testing is Prognostic of Survival Outcomes in Post-Surgical CRC Patients.
From: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Kaplan-Meier estimates for disease-free survival stratified by ctDNA-negative (blue) and ctDNA-positive (red) status at 4-weeks post-surgery in patients by pathological stage: A. Stage I, B. Stage II, C. Stage III, and D. Stage IV CRC. Hazard ratio (HR) and 95% confidence interval (CI) were calculated by the Cox proportional hazard model. P-value was calculated using the two-sided log-rank test.
